ABL1 G250E

CI-VAR-00001680Explore in graph →NP_005148.2:p.Gly250GluNM_005157.5:c.749G>AClinVar 376086 CIViC 1023 rs121913453

Curated evidence

Evidence by cancer (22 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–22 of 22 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive19
BCR::ABL1 Fusion AND ABL1 G250E	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4320 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed higher incorporation when harboring fusions with the … (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 G250E	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4321 In an in vitro study, pro-B Ba/F3 cell line expressing G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 1120.7nM)… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm3
BCR::ABL1 Fusion AND ABL1 G250E	Dasatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID9083 In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to dasatinib treatment (IC50: … (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 G250E	Bafetinib + ImatinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID7853 In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) trea… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 G250E	Nilotinib	Predictive	D	Does Not Support Resistance	3	accepted	EID2649 In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib treatment (IC50: 86… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic